Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.

doi:10.1016/j.cancergen.2026.04.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.

Cancer genetics - 1 Jun 2026

Harb Nuwar, Romey Marcel, Grass Albert, von Kügelgen Florentin, Hattesohl Akira, Schäfer Jonas A, Frey Lukas, Mack Elisabeth, Rinke Anja, Brendel Cornelia, Gremke Niklas, Gschnell Martin, Görg Marvin, Faoro Charis, Riera-Knorrenschild Jorge, Gehring Sonja, Litmeyer Anne-Sophie, Maurer Elisabeth, Adeberg Sebastian, Frickel Nadine, Keber Ursula, Nimsky Christopher, Ruchholtz Steffen, Bartsch Detlef K, Burchert Andreas, Rohde Gernot, Stuck Boris A, Groeben Christer, Gress Thomas M, Wilhelm Christian, Hoffmann Jörg, Rodepeter Fiona, Wagner Uwe, Neubauer Andreas, Jesinghaus Moritz, Wündisch Thomas, Denkert Carsten, Teply-Szymanski Julia

Abstract excerpt

BACKGROUND AND PURPOSE: Personalized medicine is guided by an expanding array of molecular targets. This study investigates whether larger next-generation sequencing (NGS) gene panels (> 1 Mb) yield more clinically relevant therapy options in molecular tumor boards (MTB) compared to smaller panels. PATIENTS AND METHODS: We analyzed 281 consecutive patients using a 430-gene DNA panel (1.3 Mb) combined with a...

Topics

Humans
Precision Medicine
High-Throughput Nucleotide Sequencing
Neoplasms
Female
Male

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Middle Aged

Aged

Biomarkers, Tumor

Mutation

Adult

Medical Oncology

Source

Open in PubMed

Identifiers

PMID: 41950859
DOI: 10.1016/j.cancergen.2026.04.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline - relevance for additional therapeutic options.PMID 41950859Read ↗

Advances in Personalized OncologySemantic proximity Read ↗

Molecular Tumor Boards: Realizing Precision Oncology Therapy.Semantic proximity Read ↗

Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Semantic proximity Read ↗

Translational and clinical comparison of whole genome and transcriptome to panel sequencing in precision oncologySemantic proximity Read ↗

Widespread adoption of precision anticancer therapies after implementation of pathologist-directed comprehensive genomic profiling across a large US health systemSemantic proximity Read ↗

Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor boardSemantic proximity Read ↗

Advancing molecular tumour boards: highly needed to maximise the impact of precision medicineSemantic proximity Read ↗

Molecular profiling for precision cancer therapiesSemantic proximity Read ↗

The Genomic Era of Clinical Oncology: Integrated Genomic Analysis for Precision Cancer CareSemantic proximity Read ↗

Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging ApplicationsSemantic proximity Read ↗

Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trialSemantic proximity Read ↗

The molecular tumor board—a key element of precision oncologySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.